Top Railroad Companies To Own In Right Now

Source: CSX.

Earlier this week, CSX (NYSE: CSX  ) saw its stock soar by 10% as news emerged that North American peer Canadian Pacific (NYSE: CP  ) had reportedly approached CSX with a possible merger deal. Yet even as investors speculated about the possible implications of a merger on the short-term value of their holdings, CSX's earnings the following afternoon gave the railroad's shareholders plenty of reasons not to want to give Canadian Pacific the chance to buy them out at what could prove to have been a bargain price.

Merger bids often result in huge short-term profits for those who've just bought shares of a stock. Yet if you're a long-term investor rather than a short-term trader, you'll often find yourself opposed to merger bids, especially if they come at an inopportune time for the company. As CSX's earnings show, the railroad is firing on all cylinders right now, and that should make investors want to turn down the chance at a quick gain in favor of the longer-term growth prospects that CSX has in a healthy and growing market.

10 Best Construction Stocks To Buy Right Now: Antares Pharma Inc (ATRS)

Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�� subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.

In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies.

Pressure Assisted Injection Devices

The Company�� Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable pl! astic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.

Disposable pressure assisted auto injectors is a technology of controlled pressure delivery of drugs into the body utilizing a spring power source. The Vibex is designed to provide fast subcutaneous or intramuscular injections of up to 0.5ml with minimal discomfort and improved convenience in conjunction with the enhanced safety of a shielded needle. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.

The Vision/Tjet has been sold for use in more than 30 countries to deliver either insulin or hGH. The product features a reusable, spring-based power source and disposable needle-free syringe, which acts as the pathway for the injectable drug through the skin and allows for viewing of the medication dose prior to injection. The product is also reusable, with each device designed to last for approximately 3,000 injections (or approximately two years) while the needle-free syringe, when used with insulin or hGH, is disposable after approximately one week when used by a single patient for injecting from multi-dose vials. The Vision/Tjet administers injectables by using a spring to push the active ingredient in solution or suspension through a micro-fine opening in the needle-free syringe. The opening is approximately half the diameter of a 30-gauge needle. The Vision/Tjet is primarily used in the United States, Europe, Asia and Japan.

Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies. Its Vibex disposable product combines a low-energy, spr! ing-based! power source with a hidden needle, which delivers up to 0.5ml of the needed drug solution subcutaneously or intramuscularly. Antares is also developing a Vibex MTX auto injector for delivery of methotrexate for treatment of rheumatoid arthritis. The Company�� multi use, disposable pen injector complements its portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi- dose cartridges. The disposable pen is in the stage of development where devices are being used in clinical evaluations.

Transdermal Products

The Company�� ATD system penetrates the skin to deliver a variety of treatments. The gels consist of a hydro-alcoholic base, including a combination of permeation enhancers. Products being developed/ commercialized include Anturol, Elestrin and Nestragel. Elestrin is a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Its other injectable drugs that are presently self-administered and may be suitable for injection with its systems include therapies for the prevention of blood clots and treatments for multiple sclerosis, migraine headaches, inflammatory diseases, impotence, infertility, acquired immune deficiency symdrome (AIDS) and hepatitis.

The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Watson, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.

Advisors' Opinion:

• [By Keith Speights]

  1. Antares Pharma (NASDAQ: ATRS  )
  Antares has experienced a roller-coaster ride so far this year. The stock was up more than 10% early in January, then proceeded to fall by more than 20% by late February. Since then, Antares has clawed its way back and now stands up a little over 10% for the year.�

• [By MONEYMORNING]

  That's not always the case. I watched as one well-known blogger on The Street sabotaged Antares Pharma (Nasdaq: ATRS) right after FDA approval for a new rheumatoid arthritis delivery system a few months ago, and it's taken a long time for ATRS to finally recover. A similar thing happened to Sangamo Biosciences (Nasdaq: SGMO), which stopped my subscribers out of the stock. I advised them to buy right back into it, and we currently just exited with a 73.4% return on it.

Top Railroad Companies To Own In Right Now: Bonavista Energy Corp (BNPUF.PK)

Bonavista Energy Corporation (Bonavista) is engaged in the acquisition, exploration, development and production of oil and natural gas assets. The Company operates approximately 87% of its assets which are concentrated within three core regions in western Canada. Each core region contains a well-balanced portfolio of oil and natural gas assets with considerable opportunities. Its operations are geographically focused within three regions of Western Canada, which includes Western region, Northern region and Eastern region. The Company�� subsidiaries include Bonavista Petroleum (BP), Bonavista Energy LP (BELP) and Bonavista Energy Inc. (BEI). Advisors' Opinion:

• [By Stephan Dube]

  Cold Lake's most notable producers:

  Husky Energy (HUSK.PK), see article here.Pengrowth Energy Corporation (PGH), see article here.Southern Pacific Resource (STPJF.PK), see article here.Canadian Natural Resources (CNQ), see article here.Devon Energy (DVN), see article here.Imperial Oil (IMO), see article here.Baytex, see article here.Bonavista Energy (BNPUF.PK), see article here.

  Athabasca's most notable producers:

Top Railroad Companies To Own In Right Now: Seattle Genetics Inc.(SGEN)

Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

Advisors' Opinion:

• [By Roberto Pedone]

  Another biotechnology player that insiders are loading up on here is Seattle Genetics (SGEN), which develops and commercializes antibody-based therapies for the treatment of cancer. Insiders are buying this stock into modest weakness, since shares are down by just 4.4% so far in 2014.

  Seattle Genetics has a market cap of $4.6 billion and an enterprise value of $4.3 billion. This stock trades at a premium valuation, with a price-to-sales of 16.7 and a price-to-book of 20.7. Its estimated growth rate for this year is -29.4%, and for next year it's pegged at 16.7%. This is a cash-rich company, since the total cash position on its balance sheet is $339.56 million and its total debt is zero.

  A director just bought 1,653,925 shares, or about $57.15 million worth of stock, at $33.71 to $36.57 per share.

  From a technical perspective, SGEN is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. This stock has been uptrending over the last few weeks, with shares moving higher from its low of $32.63 to its intraday high of $38.70 a share. During that uptrend, shares of SGEN have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of SGEN within range of triggering a near-term breakout trade.

  If you're in the bull camp on SGEN, then I would look for long-biased trades as long as this stock is trending above some near-term support just below $36 a share and then once it breaks out above some near-term overhead resistance levels at $39.20 a share to its 200-day moving average of $40.33 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.09 million shares. If that breakout triggers soon, then SGEN will set up to re-test or possibly take out its next major overhead resistance levels at $42.18 to $42.39 a share,

• [By Rich Bieglmeier]

  [Related -Seattle Genetics, Inc. (SGEN), Takeda Report Encouraging Data From ADCETRIS Study]

  Let's take a look at what $2 billion in ADCETRIS sales could mean for the stock price and where SGEN shares would need to trade to become a low-end large cap stock.

• [By Henry Kawabe]

  One of the variables that differentiates SMDCs from another cancer treatment in development, like Seattle Genetics' (SGEN) antibody-drug conjugates (ADC), are that SMDCs are 100-150 times smaller than an antibody. These small conjugates are able to penetrate solid tumors more effectively than large molecules ADCs. In preclinical studies, Endocyte saw a 20 to 30 fold improvement in drug concentration inside solid tumors with small molecule drug conjugates compared to large molecule drug conjugates. The small size also demonstrated faster excretion, which helped to reduce the drug's toxicity.

• [By Henry Kawabe]

  A number of analysts believe the stock of the biotech company Seattle Genetics (SGEN) has risen too high too quickly to support its current price, and have issued much lower target prices on the stocks than where it currently sits. On Thursday August 1st, Analysts at Cantor Fitzgerald issued a target price of $24 a share with a "sell" recommendation as they see the potential downside of the stock could drop 40.77% from its July 31st close. Previously, on June 10th, Zacks downgraded the stock and placed a price target of $41.20 per share. In May, analysts at UBS AG issued a price target from $30.00 to $36.00 giving the stock a "neutral" rating, while analysts at Leerink Swann issued a price target of $42.00. So far, the analysts have been wrong as Seattle Genetics has blown past their price targets, and as of August 2nd, the stock continued to rise, closing at $43.28 per share.

Top Railroad Companies To Own In Right Now: Ciber Inc (CBR)

CIBER, Inc. (CIBER) is a provider of information technology (IT), business consulting and outsourcing services. The Company is engaged in solving complex IT and business issues across industries, such as energy and utilities, telecommunications, retail, healthcare, financial services, entertainment and manufacturing. The Company operates in three segments: International, North America and IT Outsourcing. Its offerings are focused around a set of core competencies which include Application Development and Management (ADM), Enterprise Resource Planning (ERP), Customer Relationship Management, Business Intelligence and Data Warehousing, Managed Services, Testing and Quality Assurance, Mobility Services and Digital Marketing. On March 9, 2012, the Company sold its Federal division to CRGT, Inc.

International

The Company�� CIBER International division delivers a mix of ERP and custom ADM solutions. CIBER International offers a range of services covering the IT solution lifecycle to both commercial enterprises and public sector organizations. Key geographies for its International division include the Netherlands, the United Kingdom, Germany and the Scandinavian region consisting of Norway, Sweden and Denmark. The International division's enterprise solutions focus primarily on providing services related to ERP and Customer Relationship Management (CRM) software products, as well as managed services. It also provides SAP Industry Solutions, such as retail, automotive and chemicals, and it is a value-added reseller of SAP software in some international geographies. Th Company works with Microsoft to deliver ERP and CRM solutions in selected international geographies.

North America

The Company�� North America division was formed during the year ended December, 31, 2011, through the combination of its former Custom Solutions division and substantially all of its former U.S. ERP division. Its North America division is organized by and operates in a matrix! of geographies and practices. Its North America division provides ADM services, IT Strategy and Architecture, Business Intelligence/Data Warehousing, Collaborative Solutions, CRM and Supply Chain. The division also offers consulting services to support multi-package ERP solutions from vendors, including Oracle (including E-Business Suite, PeopleSoft and JD Edwards), SAP and Lawson, as well as several education management products. It is focused on industry solutions for vertical markets, such as telecommunications, healthcare, manufacturing, financial services, technology, state and local governments, higher education and entertainment.

The Company designs and develops custom-tailored offerings to suit its client's business needs. Its custom solutions provide a range of application portfolio management support, including analysis, design, development, testing, implementation, outsourcing and maintenance of business applications. Its service-oriented architectures, including J2EE and .NET, as well as traditional client/server and mainframe development. The Company also offers portal development, wireless and mobility applications and content delivery. The North America division is an Oracle Platinum Partner, which is a partnership in the Oracle Partner Network Specialized Program and a strategic partner to Oracle in several key industries, such as the public sector, higher education and food and beverage. Its Oracle, PeopleSoft and JD Edwards solutions involve building, integrating and supporting mission critical systems for real-time enterprises.

The Company�� North America division also is an SAP-certified global provider of application management services. The division's SAP solutions support their customers throughout the life cycle and include implementations and upgrades, extensions, integrations and customizations. The North America division has organized its SAP Practice to serve multiple vertical markets. In its SAP Commercial Practice, the North America division foc! uses on c! ustomers in retail, apparel and footwear, mining, metals, manufacturing, financial services and aerospace and defense industries. In its SAP Public Sector Practice, the North America division focuses on delivering solutions to state and local governments.

The North America division is a Certified Lawson Consulting Partner, providing business transformation projects in Lawson's target vertical markets through business process, change management and functional and technical services around Lawson technology. These target markets are healthcare, public sector, food and beverage and general manufacturing, for which it offers budgeting, financial processing and analysis, human capital management, sales order processing and manufacturing systems solutions.

IT Outsourcing

The Company�� IT Outsourcing division is a global business with domestic headquarters in Edison, New Jersey, and international presence throughout Europe. The division offers outsourced enterprise infrastructure management solutions, including managed hosted infrastructure, end user service desk and desktop services, remote infrastructure management (RIM) and application operations support. The IT Outsourcing division's data centers, service desk centers and global operations are located in the United States, United Kingdom, Poland, India and Spain. The division's Technology Solutions Group Practice focuses on providing customers with the infrastructure products and architecture. Offerings include enterprise servers, storage, middleware, integration services, assessments and related products required to support critical business applications.

The Company competes with Accenture plc, Cognizant Technology Solutions Corp, Infosys Technologies Limited, Perficient, Inc., Sapient Corp and The Hackett Group, Inc.

Advisors' Opinion:

• [By Seth Jayson]

  Ciber (NYSE: CBR  ) is expected to report Q2 earnings on July 30. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Ciber's revenues will drop -4.8% and EPS will grow from $0.00 per share the prior year.